The presence of mono- or biallelic TP53 alterations is considered a poor prognostic sign, as it is associated with resistance to conventional therapies, higher relapse rates, and significantly worse overall survival, underscoring its role as an indicator of adverse outcomes in both therapy-related and de novo myelodysplasia or AML [145]. Here, TP53 is linked to acute myeloid leukemia.